{
    "clinical_study": {
        "@rank": "11801", 
        "brief_summary": {
            "textblock": "To determine the MTD and dose-limiting toxicities of recombinant interleukin-2 (aldesleukin;\n      Proleukin) administered subcutaneously in HIV-seropositive patients. To identify a tolerable\n      subcutaneous regimen that will replicate the immunologic improvement demonstrated in the\n      outpatient polyethylene glycolated IL-2 and high-dose continuous infusion IL-2 studies. To\n      evaluate the incidence and level of anti-IL-2 antibody formation to subcutaneously\n      administered Proleukin in this patient population."
        }, 
        "brief_title": "A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will receive subcutaneous Proleukin, and the MTD will be determined."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Documented HIV infection by ELISA and Western blot.\n\n          -  CD4 count > 200 cells/mm3.\n\n        Required:\n\n          -  FDA-approved antiretroviral therapy for at least 2 months prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002107", 
            "org_study_id": "085A", 
            "secondary_id": "CS-L293-09"
        }, 
        "intervention": {
            "intervention_name": "Aldesleukin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Aldesleukin"
        }, 
        "keyword": [
            "Interleukin-2", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94114"
                }, 
                "name": "Davies Med Ctr / c/o HIV Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "citation": "Follansbee SE, Lacarrubba S, Fyfe G. Dose-ranging study of interleukin II (IL-2) in HIV-infected men on antiretroviral therapy (ARV). Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:142 (abstract no 419)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002107"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiron Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1995"
    }, 
    "geocoordinates": {
        "Davies Med Ctr / c/o HIV Institute": "37.775 -122.419"
    }
}